Prolactin Interpretation by Decade of Life

What Prolactin Actually Does and Why Clinicians Measure It

Prolactin is a 199-amino-acid polypeptide secreted by lactotroph cells in the anterior pituitary. Its best-known role is stimulating lactation, but it also modulates immune function, gonadal steroidogenesis, and central dopaminergic tone across both sexes throughout the entire lifespan.

The dopamine connection

Prolactin secretion is tonically suppressed by hypothalamic dopamine traveling down the tuberoinfundibular pathway. Any event that reduces dopamine signaling, including dopamine-blocking medications, pituitary stalk compression, or hypothyroidism, raises prolactin. This single pathway explains why so many unrelated drugs and diseases converge on hyperprolactinemia as a final common outcome. Endocrine Society Clinical Practice Guideline on hyperprolactinemia notes that antipsychotics and metoclopramide are among the most common drug causes. [1]

Why hormone-optimization patients care

Elevated prolactin suppresses GnRH pulsatility, which in turn lowers LH and FSH, producing a form of secondary hypogonadism. In men, this manifests as low testosterone, erectile dysfunction, and reduced spermatogenesis. In women, it causes oligomenorrhea, anovulation, and low estradiol. The effect is dose-dependent: in one prospective cohort of 271 hyperprolactinemic men, serum testosterone fell by approximately 40% in subjects with prolactin above 40 ng/mL compared with prolactin-normal controls. [2]

Normal Prolactin Ranges: Lab Values vs. Functional Targets

Most hospital laboratories report prolactin reference intervals derived from large, mixed-age populations. Those population-based ranges include people with subclinical hyperprolactinemia, obesity, and stress-elevated draws, which inflates the upper bound.

Laboratory reference intervals

| Population | Typical Lab Upper Limit | |---|---| | Men (adult) | 17 to 18 ng/mL | | Women (non-pregnant, premenopausal) | 25 to 29 ng/mL | | Women (postmenopausal) | 10 to 15 ng/mL | | Pregnant women (third trimester) | Up to 300 ng/mL |

Data from the Endocrine Society guideline place the diagnostic threshold for hyperprolactinemia at consistently above 25 ng/mL in women and above 20 ng/mL in men across two separate draws. [1]

HealthRX functional target

HealthRX physicians use a tighter functional window of 5 to 15 ng/mL for non-pregnant adults who are pursuing hormone optimization, TRT, or GLP-1-based metabolic programs. The rationale: values in the 15 to 25 ng/mL range, while technically "normal," associate with measurable reductions in LH amplitude in controlled pulsatility studies. The lower bound of 5 ng/mL matters too, since prolactin below 3 ng/mL has been associated with reduced immune surveillance and poorer sleep architecture in small observational studies. Draw conditions (fasting, mid-morning, no vigorous exercise within 2 hours) tighten within-person coefficient of variation from roughly 25% down to under 10%, making the functional window clinically actionable.

Prolactin by Decade: What to Expect and What to Investigate

Adolescence (ages 13 to 19)

Prolactin rises during puberty under estrogen stimulation. Girls reach mean prolactin concentrations of 10 to 17 ng/mL by late puberty; boys typically remain at 6 to 12 ng/mL. A value above 25 ng/mL in a teenager of either sex warrants pituitary MRI to rule out a prolactinoma, since adolescent prolactinomas tend to be larger and more symptomatic than those discovered in adults. [3] Galactorrhea in a teenage boy is essentially diagnostic of significant hyperprolactinemia until proven otherwise.

The Twenties: Peak Reproductive Years

In women in their 20s, prolactin fluctuates dramatically with the menstrual cycle, pregnancy, and breastfeeding. A single elevated value during the luteal phase may reflect physiologic variation rather than pathology. The Endocrine Society guideline recommends confirming hyperprolactinemia on two separate morning, fasting draws before initiating workup. [1]

Men in their 20s generally maintain prolactin at 5 to 12 ng/mL. A reading above 25 ng/mL in a young man demands investigation: medications first (antipsychotics, SSRIs, opioids, H2-blockers), then serum TSH to exclude hypothyroidism, then pituitary MRI if no drug cause is found. [1]

The Thirties: Fertility Decisions and First TRT Conversations

Women in their 30s who present with secondary amenorrhea have prolactin-secreting tumors as the cause in roughly 20% of cases. [4] A pituitary MRI without gadolinium (followed by gadolinium if a lesion is seen) is the imaging study of choice per Endocrine Society guidance.

Men in their 30s starting TRT often have a concurrent prolactin drawn as part of a secondary hypogonadism workup. If prolactin is above 17 ng/mL on a fasting morning draw and TSH is normal, checking a pituitary MRI before starting exogenous testosterone is standard of care at HealthRX. Exogenous testosterone itself does not raise prolactin, but missing a prolactinoma before TRT masks the symptom of low testosterone that would otherwise prompt investigation.

The Forties: Perimenopause and Metabolic Shifts

Prolactin begins to decline in women approaching menopause as estrogen fluctuates downward. Mean values in perimenopausal women fall to roughly 10 to 20 ng/mL. However, obesity independently raises prolactin: a cross-sectional analysis of NHANES data showed that prolactin was approximately 15% higher in women with BMI >30 compared with BMI <25, likely via altered dopamine sensitivity in hypothalamic circuits modulated by leptin signaling. [5]

Men in their 40s show stable or very slightly declining prolactin. An elevated prolactin at this age combined with low morning testosterone (below 300 ng/dL) should prompt MRI before attributing hypogonadism to primary testicular aging. Missing a microprolactinoma at this stage means years of unnecessary testosterone therapy without treating the root cause.

The Fifties: Menopause and Andropause Context

After the final menstrual period, estrogen withdrawal causes a step-down in prolactin. Postmenopausal women average 5 to 12 ng/mL. A value above 15 ng/mL in a postmenopausal woman not on HRT should prompt evaluation, since the physiologic driver of higher prolactin has largely disappeared.

Women on estrogen-containing HRT may see prolactin rise modestly, typically by 2 to 5 ng/mL. This rise is usually not clinically significant, but HealthRX recommends rechecking prolactin 3 months after initiating any estrogen-based protocol to establish a new individual baseline.

Men in their 50s pursuing testosterone optimization should have prolactin checked annually. The prevalence of previously undiagnosed pituitary adenomas found incidentally on brain MRI rises with age, reaching approximately 14.4% in autopsy studies. [6] Most are microadenomas (<10 mm) and most are nonfunctioning, but a small fraction are prolactin-secreting.

The Sixties and Beyond: Longevity Medicine Considerations

Prolactin tends to plateau or decline slightly in older adults of both sexes. In men over 60, mean prolactin runs between 4 and 9 ng/mL in population studies. A value in the higher normal range (12 to 17 ng/mL) in a 65-year-old man on opioids for chronic pain is very likely drug-induced rather than tumor-mediated, but the workup sequence remains the same: rule out medications, check TSH, then image if unexplained.

Emerging longevity research has examined prolactin in the context of immunosenescence. A 2020 study published in Aging Cell found that prolactin receptor signaling modulates NK-cell cytotoxicity, suggesting that extremely low prolactin (<3 ng/mL) in older adults may not be entirely benign. [7] This finding has not yet changed clinical guidelines, but it informs the HealthRX lower bound of 5 ng/mL as a floor worth maintaining.

Causes of Elevated Prolactin: A Systematic Approach

Physiologic causes

Prolactin rises with pregnancy, breastfeeding, nipple stimulation, sleep, stress, and vigorous exercise. These are not pathologic. Draw timing and patient preparation matter enormously.

Drug-induced hyperprolactinemia

Dopamine antagonists are the largest drug category. Antipsychotics (both first- and second-generation), metoclopramide, domperidone, and some antiemetics can push prolactin to 25 to 100 ng/mL. SSRIs cause modest elevations, typically under 5 ng/mL above baseline. Opioids impair dopamine tone and raise prolactin; this is one of the underappreciated mechanisms behind opioid-induced hypogonadism. [8]

A 2021 review in the Journal of Clinical Endocrinology and Metabolism identified 72 drugs across 15 pharmacologic classes with documented prolactin-elevating effects, confirming that a complete medication reconciliation must precede any pituitary imaging. [9]

Pituitary adenomas

Prolactinomas are the most common secreting pituitary tumors, accounting for roughly 40% of all pituitary adenomas. Microadenomas (<10 mm) typically produce prolactin between 25 and 200 ng/mL. Macroadenomas (>10 mm) frequently generate values above 200 ng/mL. The "hook effect" can falsely lower measured prolactin when levels are extremely high (greater than 1,000 ng/mL); always dilute the sample if a macroadenoma is clinically suspected but prolactin reads unexpectedly low. [1]

Other medical causes

Hypothyroidism raises TRH, which stimulates prolactin release. Check TSH before ordering pituitary MRI. Chronic kidney disease reduces prolactin clearance; values of 30 to 80 ng/mL are not unusual in dialysis patients. Chest wall injury, herpes zoster in the T4 dermatome, and cirrhosis also raise prolactin through various afferent pathways. [1]

Treating Hyperprolactinemia: Cabergoline as the Standard

Cabergoline (a D2 receptor agonist) is the first-line pharmacologic treatment for both prolactinomas and non-tumor hyperprolactinemia, per Endocrine Society guidelines. [1] The standard starting dose is 0.25 mg twice weekly, titrated upward by 0.25 mg per dose every 4 weeks based on prolactin response.

Efficacy data

In the key multicenter trial comparing cabergoline with bromocriptine (N=459), cabergoline normalized prolactin in 83% of patients vs. 59% with bromocriptine, with substantially lower rates of nausea and discontinuation. [10] Tumor shrinkage of at least 50% occurred in 68% of macroadenoma patients after 24 months of cabergoline therapy.

Cardiac safety at low doses

High-dose cabergoline (used in Parkinson disease, often 3 to 5 mg per day) associates with valvular heart disease. The doses used for hyperprolactinemia (0.25 to 2 mg per week) do not carry the same signal. A systematic review of 9 studies and 2,256 patients found no statistically significant increase in valvular abnormalities at weekly cumulative doses below 2 mg. [11] Annual echocardiographic monitoring is not required at standard hyperprolactinemia doses per current guidelines, though HealthRX orders a baseline echo for any patient needing doses above 1 mg per week.

Monitoring after treatment

Recheck prolactin 4 weeks after each dose adjustment. Once prolactin is in the functional target range (5 to 15 ng/mL) for 3 consecutive monthly draws, extend monitoring to every 6 months. For patients on TRT or HRT concurrently, prolactin should be part of every 6-month panel regardless of prior normalization.

Macroprolactin: The Common False Positive

Macroprolactin is a high-molecular-weight complex of prolactin bound to IgG antibody. It is biologically inactive but measured by most immunoassays, producing apparent hyperprolactinemia in an otherwise asymptomatic patient. Macroprolactin accounts for approximately 10 to 25% of all hyperprolactinemia diagnoses in unselected populations. [12]

If a patient has an elevated prolactin but no symptoms (normal menses, normal libido, no galactorrhea), request a polyethylene glycol (PEG) precipitation test. If more than 60% of immunoreactivity precipitates out, the sample contains macroprolactin and no further workup is needed. This single step prevents unnecessary MRI scans and unnecessary cabergoline prescriptions every year.

Prolactin and Secondary Hypogonadism: The Mechanism Matters for Treatment

Secondary hypogonadism caused by hyperprolactinemia responds to prolactin normalization, not to exogenous testosterone alone. Treating such a patient with testosterone without addressing the elevated prolactin leaves the underlying hypothalamic suppression in place and, in the case of a growing prolactinoma, allows a pituitary tumor to expand undetected.

The Endocrine Society states: "In men with hypogonadism due to hyperprolactinemia, dopamine agonist therapy to normalize prolactin levels is recommended as the primary treatment to restore gonadal function." [1] This is the clinical scenario where confirming the cause before prescribing matters most.

Once prolactin normalizes, LH, FSH, and testosterone typically recover within 3 to 6 months without testosterone replacement. If testosterone remains low after 6 months of normalized prolactin, then primary or mixed hypogonadism is likely and testosterone therapy becomes appropriate.

Draw Protocol: Getting a Reliable Result

A poorly timed or poorly collected prolactin draw is one of the most common sources of unnecessary workup in outpatient endocrinology. Follow this protocol to minimize pre-analytical error:

• Draw between 08:00 and 10:00 (after the sleep-related nocturnal surge has cleared).
• Patient should be fasting or have eaten only a light, low-protein breakfast.
• Avoid vigorous exercise for at least 2 hours before draw.
• No sexual activity or nipple stimulation within 24 hours.
• Patient should rest quietly for 30 minutes before venipuncture (eliminate stress-induced transient elevation).
• If the first draw is above 25 ng/mL, confirm with a second draw on a separate morning before initiating workup.

Following this protocol reduces false-positive rates substantially. One prospective study of 162 patients referred for hyperprolactinemia found that 26% had normal prolactin on repeat fasting draw after proper preparation, avoiding pituitary MRI in more than one in four referred patients. [13]